Is the Contineum Therapeutics (CTNM) investment thesis intact?

It is under pressure. Readouts currently rates the Contineum Therapeutics Thesis Challenged. PROPEL-IPF expands its site network; PIPE-791 efficacy remains central.

How long will Contineum Therapeutics' cash last?

Contineum Therapeutics has said its cash will fund operations through mid-2029 (guidance as of November 3, 2026). It reported $245 million in cash as of September 30, 2026.

CTNMContineum Therapeutics, Inc.

Market reactionShares rose 11% on Nov 6.

ChallengedLast material event Sep 14, 2026 · Updated Nov 3, 2026

PROPEL-IPF expands its site network; PIPE-791 efficacy remains central

Contineum Therapeutics is a clinical-stage company developing oral drugs for fibrotic and inflammatory diseases, led by PIPE-791 for idiopathic pulmonary fibrosis; none of its products is approved.

Contineum's case rests on PIPE-791, an oral LPA1 antagonist in Phase 2 PROPEL-IPF, measuring lung function over 26 weeks with completion estimated in June 2028. The expanded site network supports enrollment, while Johnson & Johnson evaluates PIPE-307 after its depression endpoint miss. Cash, equivalents and marketable securities were $244.5 million at September 30, 2026, following ATM share sales yielding $19.4 million net. Management expects funding through mid-2029. Chronic pain remains an exploratory opportunity.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

PROPEL-IPF shows PIPE-791 slows lung function declineAwaiting evidencePatient enrollment progress, followed by completion estimated in June 2028 and lung-function results.Next: Patient enrollment progress, followed by completion estimated in June 2028 and lung-function results.

Why it is in this state

The evidence, what would weaken it and the source filing

Johnson & Johnson decides on PIPE-307Awaiting evidenceJohnson & Johnson's decision on further PIPE-307 development.Next: Johnson & Johnson's decision on further PIPE-307 development.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts past the IPF readoutSupportedNext financial report's spending and runway guidance relative to PROPEL-IPF completion.Next: Next financial report's spending and runway guidance relative to PROPEL-IPF completion.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

PROPEL-IPF lung-function results

Tests: PROPEL-IPF shows PIPE-791 slows lung function decline

Trial completion estimated in June 2028; results timing not specified.

Does PIPE-791 slow lung-function decline versus placebo over 26 weeks with acceptable safety?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical

-6.8%Sep 14, 2026

PROPEL-IPF expands its site network; PIPE-791 efficacy remains central

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Idiopathic pulmonary fibrosis

PIPE-791 · 1 upcoming · 1 completed

Phase 2 Data: ToplinePROPEL-IPF

Jun 2028

Major depressive disorder

JNJ-5120 (PIPE-307) · 1 completed

Phase 2 Data: ToplineMOONLIGHT-1

Reported Sep 14, 2026

Osteoarthritis, low back pain

PIPE-791 · 1 completed

Phase 1b Data: Topline

Reported Apr 30, 2026

Relapsing-remitting multiple sclerosis

PIPE-307 · 1 completed

Phase 2 Data: ToplineVISTA

Reported Nov 20, 2025

IPF, progressive multiple sclerosis

PIPE-791 · 1 completed

Phase 1b Data: Topline

Reported Sep 18, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Contineum Therapeutics (CTNM) investment thesis intact?: It is under pressure. Readouts currently rates the Contineum Therapeutics Thesis Challenged. PROPEL-IPF expands its site network; PIPE-791 efficacy remains central.
How long will Contineum Therapeutics' cash last?: Contineum Therapeutics has said its cash will fund operations through mid-2029 (guidance as of November 3, 2026). It reported $245 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Chronic pain: Xenon Pharmaceuticals (XENE)
Idiopathic pulmonary fibrosis: Rein Therapeutics (RNTX)
Major depressive disorder: Aytu BioPharma (AYTU)Biohaven (BHVN)Definium Therapeutics (DFTX)Cybin D/B/A Helus Pharma (HELP)Lipocine (LPCN)

Disease areas: Neurology and pain, Psychiatric disorders, Lung and respiratory diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

22 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.